黄芪有效成分治疗充血性心力衰竭的核心脏病学研究

Nuclear Cardiology Study on Effective Ingredients of Astragalus Membranaceus in Treating Heart Failure

应用黄芪有效成分黄芪甙Ⅳ（ＸＧＡ）注射液治疗１９例充血性心力衰竭的患者，２周后１５例患者胸闷、气急症状好转，活动能力有所提高。以放射性核素心血池造影术观察示左心室构型改善：即左室舒张末期容积缩小（从１０１．２４±４５．３６ｍｌ到８９．８６±４４．１３ｍｌ）．左室收缩末期容积也缩小（从７８．８０±４２．２５ｍｌ到６１．６８±３３．４１ｍｌ），此两项变化均有显著性差异（Ｐ＜０．０５）；心率减慢（从８８．２１±１７．１９次／ｍｉｎ到６４．５５±１３．０６次／ｍｉｎ，Ｐ＜０．０５）；峰射血率增加（从１．８０±０．８６ｕ／ｓ到１．９５±０．８５ｕ／ｓ，Ｐ＜０．０５）。左室射血分数、峰充盈率有所升高，但无统计学意义。提示ＸＧＡ注射液是非洋地黄类的有效正性肌力药物，连续应用２周后可改善充血性心力衰竭患者的左室构型和射血功能。

The experimental study has testified that among the various effective constituents gained from Astragalus membranaceus(AM) is the main component.Nineteen patients with heart congestive failure were treated with effective ingredient of AM,the astragaloside Ⅳ(XGA) injection.Results:after 2 weeks of treatment the symptoms of chest distress,dispnea in 15 patients was alleviated,their capability of exercise reinforced.Radionuclide ventriculography showed that left ventricular modelling improved,left ventricular end-diastolic volume diminished by 11.74±18.39 ml,left ventricular end-systolic volume by 9.35±18.01 ml,with statistical significance.HR slowed from 88.21±17.19 to 64.55±13.06 beats/min,P<0.05,PER increased from 1.80±0.86 to 1.95±0.85 u/second,P<0.05.Left ventricular EF,PFR increased also at some extent without statistical significance.Conclusion:effective ingredient of AM,XGA injection is efficient positive inotropic drug, and could improve the left ventricular modelling and ejection function in patients with congestive heart failure after continuous administration of XGA injection for two weeks.